RCT to Evaluate the Efficacy and Safety of Ivy Leaves Cough Liquid vs. Placebo in the Treatment of Acute Cough

Phase 2

Completed

• Conditions: Acute Cough
• Interventions: Drug: Ivy Leaves Cough Liquid; Drug: Placebo

• Registration Number: NCT02396706
• Lead Sponsor: Engelhard Arzneimittel GmbH & Co.KG

Brief Summary

Randomized, controlled, double-blind, multi-center trial to evaluate the efficacy and safety of a liquid containing ivy leaves dry extract vs. placebo in the treatment of acute cough

Detailed Description

Not available

Study Timeline

• Study Start: 2015-01
• Study First Submitted: 2015-03-18
• Study First Submitted QC: 2015-03-23
• Study First Posted: 2015-03-24
• Primary Completion: 2015-06
• Study Completion: 2015-06
• Status Verified: 2015-09
• Last Update Submitted: 2015-09-02
• Last Update Posted: 2015-09-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 181

Inclusion Criteria

1. Acute cough with symptoms lasting 2-3 days prior to treatment
2. Men or women of any ethnic origin
3. Age 18 to 75 years
4. Subjects who are able to understand and are willing to comply to trial instructions
5. Having given written informed consent
6. Satisfactory health except for the cough as determined by the investigator based on medical history and physical examination
7. CS score of at least 50 mm on a 100 mm VAS at V1
8. Acute BSS of at least 10 points at V1
9. VCD score of at least 2 points at V1

Exclusion Criteria

1. Allergic bronchial asthma, bronchial hyperreactivity, chronic bronchitis, other chronic or inherited lung disease
2. History of hypersensitivity to any excipient of the applied drugs
3. History of drug hypersensitivity, asthma, urticaria, or other severe allergic diathesis as well as current hay fever
4. History of chronic gastritis or peptic ulcers
5. Any gastrointestinal complaints within 7 days before V1
6. Participation in a clinical trial within 30 days prior to the treatment phase of this study or concomitantly
7. Treatment with corticoids, beta-2 agonists (e.g. salbutamol, fenoterol), expectorants, theophylline, antitussives, anaesthetics, acetylsalicylic acid (e.g. aspirin) or other non-steroidal anti-inflammatory drugs, leukotriene inhibitors, angiotensin-converting enzyme (ACE) inhibitors, antiviral drugs or antibiotics, antihistamines, immunosuppressants, isoprenaline, atropine, sodium cromoglycate or homeopathic drugs against common cold within 7 days before V1
8. Drug or alcohol abuse in the opinion of the investigator
9. Pregnant or nursing (lactating) women
10. Women of child-bearing potential (defined as all women physiologically capable of becoming pregnant) who are not using an acceptable method of contraception.
11. Subjects with significant diseases, defined as a disease which, in the opinion of the investigator, may either put the subject at risk because of participation in the trial or a disease which may influence the results of the trial or the subject's ability to participate in the trial; includes subjects with a history of gastrointestinal bleeding, significant cardiovascular, liver or renal disease.
12. Subjects directly or indirectly involved in the execution of this protocol, including employees of the CRO and persons related to them.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Ivy Leaves Cough Liquid	Ivy Leaves Cough Liquid	Ivy Leaves Cough Liquid
Placebo	Placebo	Placebo

Primary Outcome Measures

Name	Time	Method
Visual Analogue Scale (VAS)	whole treatment period over 7 days

Trial Locations

Locations (1)

Medizentrum Essen-Borbeck; 🇩🇪 Essen, Germany